An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma
Dongmei Fan(China Academy of Transportation Sciences), Dongsheng Xiong(Chengdu Medical College)
Cited by 4
Related Papers
Advancing Tumor-Targeted Chemo-Immunotherapy: Development of the CAR-M-derived Exosome-Drug Conjugate
|Journal of Medicinal Chemistry|2024|18
Universal Protein Trans-Splicing-Based CAR System Enabling CAR-T Cells with Reduced Exhaustion and Enhanced Efficacy
|Journal of Medicinal Chemistry|2025|1